These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21621965)

  • 21. Ixabepilone for the treatment of solid tumors: a review of clinical data.
    Denduluri N; Swain SM
    Expert Opin Investig Drugs; 2008 Mar; 17(3):423-35. PubMed ID: 18321240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current perspectives of epothilones in breast cancer.
    Cardoso F; de Azambuja E; Lago LD
    Eur J Cancer; 2008 Feb; 44(3):341-52. PubMed ID: 18178426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy.
    LaPointe NE; Morfini G; Brady ST; Feinstein SC; Wilson L; Jordan MA
    Neurotoxicology; 2013 Jul; 37():231-9. PubMed ID: 23711742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
    Steinberg M
    Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Axonal neuropathy caused by epothilone B.
    Grewal RP
    Neurol India; 2007; 55(2):178-9. PubMed ID: 17558132
    [No Abstract]   [Full Text] [Related]  

  • 27. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
    Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
    J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ixabepilone (Ixempra) for breast cancer.
    Med Lett Drugs Ther; 2008 Jan; 50(1278):7-8. PubMed ID: 18219261
    [No Abstract]   [Full Text] [Related]  

  • 29. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
    Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ixabepilone: a new antimitotic for the treatment of metastatic breast cancer.
    Bhushan S; Walko CM
    Ann Pharmacother; 2008 Sep; 42(9):1252-61. PubMed ID: 18648018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternative dosing schedules and administration updates for ixabepilone.
    Kossoff E
    J Oncol Pharm Pract; 2011 Sep; 17(3):203-8. PubMed ID: 20215481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of peripheral neuropathy caused by microtubule inhibitors.
    Donovan D
    Clin J Oncol Nurs; 2009 Dec; 13(6):686-94. PubMed ID: 19948466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management.
    Swain SM; Arezzo JC
    Clin Adv Hematol Oncol; 2008 Jun; 6(6):455-67. PubMed ID: 18567992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epothilones in breast cancer: current status and future directions.
    Atzori F; Fornier M
    Expert Rev Anticancer Ther; 2008 Aug; 8(8):1299-311. PubMed ID: 18699766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days.
    Zhuang SH; Agrawal M; Edgerly M; Bakke S; Kotz H; Thambi P; Rutt A; Balis FM; Bates S; Fojo T
    Cancer; 2005 May; 103(9):1932-8. PubMed ID: 15800893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors.
    Lam ET; Goel S; Schaaf LJ; Cropp GF; Hannah AL; Zhou Y; McCracken B; Haley BI; Johnson RG; Mani S; Villalona-Calero MA
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):523-31. PubMed ID: 21874318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Approved agents for metastatic breast cancer.
    Fornier MN
    Semin Oncol; 2011 Jun; 38 Suppl 2():S3-10. PubMed ID: 21600382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ixabepilone: new drug. Similar to taxanes, but no better.
    Prescrire Int; 2009 Aug; 18(102):160. PubMed ID: 19743574
    [No Abstract]   [Full Text] [Related]  

  • 39. Chemotherapy-induced neuropathy.
    Windebank AJ; Grisold W
    J Peripher Nerv Syst; 2008 Mar; 13(1):27-46. PubMed ID: 18346229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
    Richardson PG; Sonneveld P; Schuster MW; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Bladé J; Boccadoro M; Cavenagh JD; Boral AL; Esseltine DL; Wen PY; Amato AA; Anderson KC; San Miguel J
    Br J Haematol; 2009 Mar; 144(6):895-903. PubMed ID: 19170677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.